Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ivantis, Inc.
BTIG Analyst Zooms Into Alcon’s Revamp Into ‘Building A Pharma Company Inside A Device Company’
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Alcon Sees Big Opportunity In Glaucoma Surgery; Buys Ivantis For $475M
Ivantis markets the Hydrus Microstent for minimally invasive glaucoma surgery, a field Alcon exited three years ago when it pulled its CyPass from the market
CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
Proposed Medicare Code Change Could Affect Reimbursements On Glaucoma Devices
A proposed change to US Medicare billing that would go into effect 1 January might give one manufacturer an edge over its competitor.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.